<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01208506</url>
  </required_header>
  <id_info>
    <org_study_id>NN8828-3837</org_study_id>
    <secondary_id>2010-018347-33</secondary_id>
    <secondary_id>U1111-1116-2585</secondary_id>
    <nct_id>NCT01208506</nct_id>
  </id_info>
  <brief_title>First-in-Man Trial of NNC114-0005 in Healthy Subjects and Subjects With Rheumatoid Arthritis</brief_title>
  <official_title>First Human Dose Trial of NNC0114-0000-0005 in Healthy Subjects and Subjects With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to investigate the safety,&#xD;
      tolerability, pharmacokinetic (the effect of the body on the investigated drug),&#xD;
      pharmacodynamic biomarkers (biomarkers related to anti-IL-21 expected mode of action) and&#xD;
      signs of clinical efficacy of increasing single doses, at 9 i.v. (into the vein) dose levels&#xD;
      in Healthy Subjects , at 3 i.v. dose levels in subjects with rheumatoid arthritis (RA) and at&#xD;
      3 s.c. dose levels in Healthy Subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>at least 12 weeks after dose administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve</measure>
    <time_frame>at least 12 weeks after dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum level of free IL-21 and maximum level of bound IL-21 in peripheral blood</measure>
    <time_frame>at least 12 weeks after dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Disease Activity Score 28 (DAS28)-C-reactive protein (CRP) in subjects with RA</measure>
    <time_frame>at least 12 weeks after dose administration</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Inflammation</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0114-0000-0005</intervention_name>
    <description>A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects.</description>
    <arm_group_label>Dose level 1</arm_group_label>
    <arm_group_label>Dose level 2</arm_group_label>
    <arm_group_label>Dose level 3</arm_group_label>
    <arm_group_label>Dose level 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0114-0000-0005</intervention_name>
    <description>A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA. In addition a single dose of NNC0114-0000-0005 administered s.c. (under the skin) in healthy subjects.</description>
    <arm_group_label>Dose level 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0114-0000-0005</intervention_name>
    <description>A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. In addition a single dose of NNC0114-0000-0005 may be administered s.c. (under the skin) in healthy subjects based on safety data.</description>
    <arm_group_label>Dose level 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0114-0000-0005</intervention_name>
    <description>A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA. In addition a single dose of NNC0114-0000-0005 may be administered s.c. (under the skin) in healthy subjects based on safety data.</description>
    <arm_group_label>Dose level 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0114-0000-0005</intervention_name>
    <description>A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA.</description>
    <arm_group_label>Dose level 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>A single dose of NNC0114-0000-0005 placebo.</description>
    <arm_group_label>Dose level 1</arm_group_label>
    <arm_group_label>Dose level 2</arm_group_label>
    <arm_group_label>Dose level 3</arm_group_label>
    <arm_group_label>Dose level 4</arm_group_label>
    <arm_group_label>Dose level 5</arm_group_label>
    <arm_group_label>Dose level 6</arm_group_label>
    <arm_group_label>Dose level 7</arm_group_label>
    <arm_group_label>Dose level 8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For all subjects the following applies:&#xD;
&#xD;
          -  Male subjects, if not sterilized, must be using two acceptable methods of&#xD;
             contraception (e.g., spermicidal gel plus condom) for the entire duration of the trial&#xD;
             corresponding to up to three months following trial drug administration. Male subjects&#xD;
             must also agree to refrain from sperm donation from screening (trial start) until 120&#xD;
             days beyond trial drug administration&#xD;
&#xD;
          -  For healthy subjects (HS) the following additional criteria applies:&#xD;
&#xD;
          -  Male subjects, aged between 18 and 60 years (both inclusive) and in good health, as&#xD;
             determined by past medical history, physical examination, vital signs,&#xD;
             (electrocardiogram) ECG, and laboratory tests at screening (trial start)&#xD;
&#xD;
          -  For subjects with rheumatoid arthritis (RA) the following additional criteria applies:&#xD;
&#xD;
          -  Diagnosed with RA at least 3 months prior to trial drug administration&#xD;
&#xD;
          -  Active RA, characterised by a Disease Activity Score 28 (DAS28)-C-reactive protein&#xD;
             (CRP) greater than 3.2&#xD;
&#xD;
          -  Effective methods of contraception&#xD;
&#xD;
          -  Male and female subjects aged greater and equal to 18 and greater and equal to 75&#xD;
             years&#xD;
&#xD;
          -  Females must be post-menopausal or surgically sterile (post-menopausal for at least 1&#xD;
             year). If female of child-bearing potential must be willing to use highly effective&#xD;
             method of birth control during the trial until their final visit&#xD;
&#xD;
          -  Methotrexate treatment (MTX) treatment for at least 12 weeks at a stable dose (dose at&#xD;
             least 7.5 mg/week and maximum 25 mg/week inclusive) for at least 4 weeks prior to&#xD;
             trial product administration&#xD;
&#xD;
          -  Concomitant medication according to specific list&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  For all subjects the following applies:&#xD;
&#xD;
          -  Body mass index (BMI) between 20.0-38.0 kg/m2 (both inclusive)&#xD;
&#xD;
          -  Females with a positive pregnancy test&#xD;
&#xD;
          -  History of regular alcohol consumption exceeding 14 drinks per week for females or 21&#xD;
             drinks per week for men&#xD;
&#xD;
          -  Donation or loss of at least 400 mL of blood within 8 weeks prior to trial product&#xD;
             administration&#xD;
&#xD;
          -  For healthy subjects (HS) the following additional criteria applies:&#xD;
&#xD;
          -  Body weight greater than 110.0 kg&#xD;
&#xD;
          -  For subjects with rheumatoid arthritis (RA) the following additional criteria applies:&#xD;
&#xD;
          -  Chronic inflammatory autoimmune disease other than RA (except secondary Sjögren's&#xD;
             syndrome or stable hypothyroidism)&#xD;
&#xD;
          -  History of or current inflammatory joint disease other than RA such as gout (crystal&#xD;
             proven), psoriatic arthritis, juvenile idiopathic arthritis, current reactive&#xD;
             arthritis or Lyme disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>First in human study with recombinant anti-IL-21 monoclonal antibody in healthy subjects and patients with rheumatoid arthritis. Arthritis and Rheumatism 2012; 64 (10 (supplement)): Abstract 1279</citation>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>September 23, 2010</study_first_submitted>
  <study_first_submitted_qc>September 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2010</study_first_posted>
  <last_update_submitted>February 6, 2017</last_update_submitted>
  <last_update_submitted_qc>February 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

